Key Points {#FPar1}
==========

Internal validation, where the model trained on 75% of the data was tested on the remaining 25% of the data, showed excellent performance characteristics, with a mean area under the receiver operator characteristic curve (AUC) of 0.950 across four administrative claims databases.External validation, where the model trained on one dataset was tested on the other three datasets, showed very good to excellent performance characteristics, with AUCs ranging from 0.840 to 0.956.Accounting for subjects who received an exposure to a drug or procedure at the point in their treatment when they were in end-of-life care may improve the validity of the risk profile for those treatments.

Introduction {#Sec1}
============

Studies of medication adverse effects often exclude subjects who are in end-of-life care. This exclusion is reasonable because such subjects may use medications and receive care that is quite different from others, and because their deaths are likely to reflect their underlying risk rather than an effect of the medication being studied. Exclusion of subjects who are receiving end-of-life care is particularly important for studies of medications that may be used as part of end-of-life care and for studies that include a mortality endpoint because failure to exclude such patients would introduce confounding by indication or reverse causality bias \[[@CR1], [@CR2]\]. This study was started because one of the authors identified evidence of reverse causation in a study of the association of several gastrointestinal medications with the risk of sudden cardiac death (SCD). The study was susceptible to reverse causation because the medications were used for patients in terminal care, who were not initially recognized as being in terminal care, typically are at high risk for nausea and vomiting, and (presumably because their deaths were expected) had 'heart stopped' listed as the cause of death. Having a simple means to identify patients who are likely to be in terminal care and do a sensitivity analysis to account for these subjects provides a straightforward means of testing for this issue \[[@CR2], [@CR3]\]. There are few documented methods for retrospective studies from administrative databases to identify and exclude subjects who were receiving end-of-life care.

Two recent studies brought this issue into sharper focus. One was a study of the risk of SCD among people exposed to domperidone, a gastrointestinal motility agent useful for the treatment of nausea and vomiting \[[@CR3]\]. That study excluded subjects with cancer but did not initially exclude subjects who were receiving end-of-life care. Nausea and vomiting are common in end-of-life care. When the investigators developed an algorithm for identifying subjects who were receiving end-of-life care and excluded those subjects, the odds ratio estimate for the association of domperidone exposure and SCD fell from 2.1 to 1.7. The second study was a literature review to assess the association of the use of haloperidol in elderly patients with dementia with an increased risk of all-cause death \[[@CR4]\]. It identified six studies that reported such an association but none excluded subjects who were receiving end-of-life care, although haloperidol is commonly used for its impact on delirium and control of nausea and vomiting.

Diagnostic predictive models have been developed across a number of different circumstances in recent years, particularly in research as a method to improve outcome ascertainment, and the use of these models has increased in recent years \[[@CR5], [@CR6]\]. Demirer et al. developed a model for tuberculous pleural effusions as a method to reduce the reliance on a diagnostic test (directly sampling plural fluid and testing for Mycobacterium tuberculosis) that is invasive and often unavailable in developing countries \[[@CR7]\]. Predictive modeling was used to improve differential diagnosis of vascular parkinsonism versus Parkinson's disease as symptoms often overlap between the two, presenting a clinical challenge \[[@CR8]\]. Williams and colleagues used a predictive model to improve the pretest probability of the presence of occlusive coronary artery disease in order to select appropriate individuals for undergoing cardiac imaging \[[@CR9]\].

The objective of this study was to develop a diagnostic predictive model to determine patients in end-of-life care at the time of their last prescription for a new medication in administrative databases.

Methods {#Sec2}
=======

Databases {#Sec3}
---------

Data for this study were from data collected between 1 January 2000 and 31 January 2017 from four data sets: IBM^®^ MarketScan^®^ Medicare Supplemental Beneficiaries (MDCR; data from 1 January 2000 to 31 January 2017); IBM^®^ MarketScan^®^ Multi-State Medicaid (MDCD; data from 1 January 2006 to 30 June 2016); IBM^®^ MarketScan^®^ Commercial Claims and Encounters (CCAE; data from 1 January 2000 to 31 January 2017); and Optum^©^ De-Identified Clinformatics^®^ Data Mart Database (Optum; data from 1 May 2000 to 30 September 2016). These datasets provided a broad range of subjects for the study, including those under age 65 years (CCAE and Optum), those over age 65 years (Optum and MDCR), and individuals of lower socioeconomic status (MDCD). The study dates were chosen based on the full set of data available for purchase from the data vendors at the time of analysis. Each dataset was converted to the Common Data Model (CDM), version 5.01, developed by the Observational Health Data Sciences and Informatics (OHDSI) interdisciplinary collaborative \[[@CR10]\]. The Optum and IBM MarketScan databases used in this study were reviewed by the New England Institutional Review Board (IRB) and were determined to be exempt from broad IRB approval as this research project did not involve human subject research.

Prediction Model Specification {#Sec4}
------------------------------

### Target Population {#Sec5}

Subjects were included in the study if they were 40 years of age or older and had a diagnosis of cancer, heart failure, respiratory failure, dementia, Parkinson's disease, liver failure, and/or renal failure on or prior to the index date. These conditions were chosen as a way to include those subjects more likely to be in end-of-life care and therefore of concern to a researcher conducting a study with a mortality endpoint. The administrative codes for the inclusion conditions are shown in the Supplementary Appendix 1 spreadsheet (Table 1 labeled 'Inclusion Concepts'). Each included subject was also required to have at least 1 year of continuous observation prior to the index date. For each subject, we identified the date of first exposure to each active ingredient, and then selected the last of those drug start dates as the subject's index date. We chose the date of the last new drug start for the index date as this would provide the most likely drug prescribed for the treatment of end-of-life care.

### Outcome {#Sec6}

The outcome of end-of-life care was determined by a set of diagnostic conditions and clinical observations, procedures, and measures codes indicative of terminal and/or hospice care (see Supplementary Appendix 1 spreadsheet, Table 2 labeled 'Outcome Concepts'). These included diagnostic conditions such as 'death imminent' and 'terminal illness', and clinical observations such as 'hospice care supervision' and 'routine admission to hospice'. These codes were developed with the aid of two physicians (co-author DF and Soledad Cepeda, MD, PhD). It should be noted that a code for death was not required in order to improve the portability of the model as many health services databases do not reliably capture out-of-hospital death.

### Time at Risk {#Sec7}

Subjects were required to have at least one of the above-mentioned codes indicative of terminal and/or hospice care within 180 days prior to the index date to be considered to have the outcome and thus be considered a 'case' of end-of-life care at the time of the prescription. End-of-life care is generally considered to be for those with \< 180 days to live, which was the rationale for deciding the period prior to the index date \[[@CR11]\].

### Covariates {#Sec8}

Covariates used in the diagnostic predictive model included demographics (sex, age, index year and month), prior conditions, drugs, procedures and measurements observed during 30, 180, 365, or all days prior to the index date, Charlson comorbidity index \[[@CR12]\], Diabetes Complications Severity Index (DCSI) score \[[@CR13]\], CHADS2 score \[[@CR14]\], and the number of distinct conditions, drugs, procedures and visits observed in the 365 days prior to the index date. Procedures included actions such as 'intravenous injection' and 'continuous infusion of therapeutic substance'. Measurements included testing such as 'albumin; urine, microalbumin, quantitative' and 'body weight'.

Covariates were included in the model if they were present in at least 25 subjects. We excluded all terminal, hospice, and palliative care concepts from model development (see Supplementary Appendix 1 spreadsheet, Table 3 labeled 'Model Exclusions').

We used the OHDSI Patient-Level Prediction software, an open source R package, to develop the model. The software implements a framework for developing diagnostic models while addressing existing best practices towards ensuring that models are clinically useful and transparent \[[@CR15]\]. We developed and tested models for each of the four databases. All prediction models were fitted using regularized logistic regression with an L~1~ (LASSO) prior \[[@CR15]--[@CR17]\]. The optimal regularization hyperparameters were estimated using tenfold cross-validation. Each model was trained on a randomly selected sample of 75% of the subjects (the 'training set') and internal validation was performed on the remaining 25% (the 'test set'). Subjects were excluded from both the test and training sets if they had the outcome prior to the index date. Internal validation was through examination of the area under the receiver operating characteristic (ROC) curve and through calibration of the model by examining the observed fraction of subjects with the outcome of end-of-life care throughout the range of predicted probabilities. External validation was through examination of the area under the ROC curve after applying the model learned on one dataset to the other three datasets.

Results {#Sec9}
=======

The number of participants, number of outcomes, and the demographic and comorbid characteristics for the four datasets analyzed in this study are displayed in Table [1](#Tab1){ref-type="table"}. Continuous variables are presented as median (interquartile range \[IQR\]) and/or mean (standard deviation \[SD\]), while categorical variables are presented as number (%). The portion of the cohort with the outcome of being in end-of-life care was older than those subjects not in end-of-life care. In the 180 days prior to the index date, those with the outcome had higher rates of each of the seven comorbid conditions used for inclusion into the cohort. The largest differences between those with the outcome and those without were in the proportion of the cohort with a recorded condition of cancer in the prior 180 days. We did not test for statistical differences between proportions of those with or without the outcome.Table 1Subject demographic and prior comorbid condition data for those in end-of-life care ('with outcome') and those not in end-of-life care ('no outcome') for the four datasets used in this studyNameCCAEMDCDMDCROptumWith outcomeNo outcomeWith outcomeNo outcomeWith outcomeNo outcomeWith outcomeNo outcomeParticipants (*N*)2199278,590187276,0771237193,7861030268,393Age, years \[mean (SD)\]56.6 (5.8)55.6 (6.7)70.6 (14.5)66.2 (13.6)82.0 (7.8)77.2 (7.7)69.1 (12.1)64.4 (12.1)Age, years \[median (IQR)\]57.5 (53.0--61.1)56.6 (50.7--61.2)71.0 (57.8--85.0)65.5 (55.2--77.7)82.3 (76.3--87.9)76.4 (70.9--82.8)72.1 (59.0--79.5)64.5 (54.9--74.3)Female1031 (46.9)142,044 (51.0)1205 (64.4)51,186 (67.3)700 (56.6)103,729 (53.5)583 (56.6)138,003 (51.4)Number of visits past 180 days \[median (IQR)\]45.0 (28.0--67.0)9.0 (5.0--17.0)26.0 (12.0--52.0)15.0 (7.0--40.0)21.0 (12.0--35.0)11.0 (6.0--20.0)39.0 (21.0--63.0)12.0 (6.0--23.0)Charlson index \[mean (SD)\]9.4 (3.5)4.0 (2.7)7.1 (4.1)5.5 (3.3)7.1 (3.6)5.3 (3.2)8.6 (3.8)4.9 (3.2)Cancer1908 (86.8)84,318 (30.3)631 (33.7)8380 (11.0)426 (34.4)50,481 (26.0)572 (55.5)72,706 (27.1)Chronic renal failure358 (16.3)16,517 (5.9)441 (23.6)9048 (11.9)245 (19.8)19,331 (10.0)229 (22.2)24,190 (9.0)Dementia85 (3.9)2198 (0.8)549 (29.3)6700 (8.8)471 (38.1)21,870 (11.3)313 (30.4)17,214 (6.4)Heart failure226 (10.3)19,966 (7.2)498 (26.6)10,689 (14.1)402 (32.5)35,179 (18.2)288 (28.0)34,311 (12.8)Liver failure98 (4.5)2034 (0.7)80 (4.3)732 (1.0)7 (0.6)563 (0.3)23 (2.2)1815 (0.7)Parkinsons disease17 (0.8)1685 (0.6)40 (2.1)639 (0.8)64 (5.2)4037 (2.1)35 (3.4)3278 (1.2)Respiratory failure349 (15.9)8164 (2.9)301 (16.1)4432 (5.8)153 (12.4)9867 (5.1)133 (12.9)12,239 (4.6)Data are expressed as *n* (%) unless otherwise specified*CCAE* IBM^®^ MarketScan^®^ Commercial Claims and Encounters, *MDCD* IBM^®^ MarketScan^®^ Multi-State Medicaid, *MDCR* IBM^®^ MarketScan^®^ Medicare Supplemental Beneficiaries, *Optum* Optum^©^ De-Identified Clinformatics^®^ Data Mart Database, *SD* standard deviation, *IQR* interquartile range

Each of the models showed excellent performance based on our internal validation (Table [2](#Tab2){ref-type="table"}). The AUCs after applying the model developed on the training set to the test set ranged from 0.918 in MDCR, the smallest dataset, to 0.983 in CCAE, the largest dataset. The intercepts for each of the fitted calibration curves were near 0 and the slopes of the curves were all 8% or less from unity, the ideal value indicating that the models were well calibrated \[[@CR18]\]. The AUC and calibration curves for each of the models are shown in Fig. [1](#Fig1){ref-type="fig"}.Table 2Internal validation of models on the 25% subset of the dataset held back during model training for each datasetDatasetAUC (95% CI)Calibration interceptCalibration slopeCCAE0.983 (0.978--0.987)0.0001.05MDCD0.947 (0.937--0.957)− 0.0011.06MDCR0.918 (0.905--0.930)0.0001.08Optum0.945 (0.932--0.958)0.0001.07*AUC* area under receiver operating characteristic curve, *CI* confidence interval, *CCAE* IBM^®^ MarketScan^®^ Commercial Claims and Encounters, *MDCD* IBM^®^ MarketScan^®^ Multi-State Medicaid, *MDCR* IBM^®^ MarketScan^®^ Medicare Supplemental Beneficiaries, *Optum* Optum^©^ De-Identified Clinformatics^®^ Data Mart DatabaseFig. 1Area under the receiver operator characteristic curve and calibration curves for the internal validation of the models from the four datasets used in this study

Our models also performed well on external validation (Table [3](#Tab3){ref-type="table"}). After applying a model learned on one dataset to the other datasets, the AUCs ranged from 0.840 for the CCAE-learned model applied to MDCD, to 0.956 for the MDCR-learned model applied to CCAE and for the MDCD-learned model applied to CCAE. The graphical representations of the AUCs for the external validations are shown in Fig. [2](#Fig2){ref-type="fig"}.Table 3External validation of each model when applying to the other three datasetsTrain datasetTest datasetAUC (95% CI)CCAEMDCD0.840 (0.834--0.846)MDCR0.883 (0.879--0.887)Optum0.935 (0.931--0.939)MDCDCCAE0.956 (0.952--0.960)MDCR0.879 (0.875--0.883)Optum0.909 (0.906--0.912)MDCRCCAE0.956 (0.952--0.960)MDCD0.888 (0.882--0.894)Optum0.936 (0.932--0.940)OptumCCAE0.963 (0.959--0.967)MDCD0.868 (0.862--0.874)MDCR0.893 (0.889--0.897)*AUC* area under receiver operating characteristic curve, *CI* confidence interval, *CCAE* IBM^®^ MarketScan^®^ Commercial Claims and Encounters, *MDCD* IBM^®^ MarketScan^®^ Multi-State Medicaid, *MDCR* IBM^®^ MarketScan^®^ Medicare Supplemental Beneficiaries, *Optum* Optum^©^ De-Identified Clinformatics^®^ Data Mart DatabaseFig. 2Area under the receiver operator characteristic curves for the external validation of the models from the four datasets used in this study

The prevalence of subjects in end-of-life care is quite low in our datasets, i.e. \< 1% in CCAE, MDCR, and Optum, and 2.5% in MDCD. At low outcome prevalence, examination of the precision-recall curves is important. Figure [3](#Fig3){ref-type="fig"} shows the precision-recall curves for each of the four datasets. As expected, precision was highest in the dataset with the highest prevalence, i.e. MDCD. The curve indicates that at a recall of 0.5, the precision was about 22%, which is close to 10 times the baseline rate. This indicates that, while precision is low, the model was able to effectively discriminate between those in end-of-life care from those not in end-of-life care.Fig. 3Area under precision-recall curves for the internal validation of the models from the four datasets used in this study. The black line is the recall (sensitivity) plotted against precision (positive predictive value) and the red dashed line is the fraction of the target population who have the outcome (population average outcome risk)

The primary objective of these models was to improve the ability to predict which subjects are in end-of-life care. It is, however, possible to examine the covariates in the model to understand important predictors and to understand the similarities and differences between the models. The number of observations in the prior 180 days, the presence of malignant neoplastic disease, and dementia were among the common model-determined factors between the four datasets. Many differences existed between the models. For example, a condition of 'failure to thrive' was an important factor in the models for MDCD, MDCR, and Optum, which included many patients older than 65 years of age. It was not a factor in the CCAE model, which is composed of primarily younger individuals still in the work force. 'Asthenia' was also an important predictor in the models for MDCD, MDCR, and Optum, but not in CCAE. The number of clinical visits in the 180 days prior to the index date was a primary factor in the CCAE dataset, but not in MDCD, MDCR, or Optum. Similarly, 'motor neuron disease' was also an important predictor in CCAE, but not in the other datasets. The full prediction models for each of the datasets are shown in the Supplementary Appendix 2 spreadsheet.

Discussion {#Sec10}
==========

The results from this study show that developing diagnostic predictive models for determining subjects in end-of-life care at the time of a particular medication treatment is possible. This type of model may prove useful for improving estimates for mortality endpoints in pharmacoepidemiological studies. To our knowledge, this is the first study to develop a model for assessing subjects in end-of-life care using large-scale datasets.

We purposely used administrative codes for terminal or hospice care to develop our gold-standard cases for model development, choosing not to use palliative care codes. The World Health Organization definition of palliative care includes its applicability "early in the course of illness, in conjunction with other therapies that are intended to prolong life, such as chemotherapy or radiation therapy, and includes those investigations needed to better understand and manage distressing clinical complications" \[[@CR19]\]. In recent years, the use of palliative care has expanded to a wide range of illnesses that, while life-threatening, may not explicitly indicate end-of-life care \[[@CR20]\]. In this study, we focused on terminal or hospice care which we believe will be more relevant to future data. Our case-defining algorithm also likely had a higher specificity for determining end-of-life care than one incorporating palliative care. The predictive model developed using this initial algorithm will also have higher specificity, which is critical for studies examining mortality endpoints.

There has been little prior research using diagnostic models for determining subjects in observational studies who were in end-of-life care at the time of the exposure of interest. Guadagnolo and colleagues examined radiation treatment in the last 30 days of life to ascertain utilization of this therapy during end-of-life care \[[@CR21]\]. Those authors acknowledged that using the last 30 days of life as a criterion for end-of-life care at the time of treatment may not have accurately discriminated between the use of radiation for palliation versus curative purposes. For their study examining end-of-life cancer treatment, Huo et al. used hospice care codes to determine those in end-of-life care \[[@CR22]\]. Those authors cited prior studies examining the many factors involved in a patient's use of hospice care, including sex, marital status, hospice availability, and changes in attitudes toward death over time \[[@CR23]--[@CR25]\]. Following the publication of that study, several other studies have found that factors such as cancer type, physician preference, and geography also affect the decision to enter hospice care \[[@CR26]--[@CR28]\]. These limitations may have significantly reduced the sensitivity of this method for ascertainment of those in end-of-life care. The current study complements the works of Avati and colleagues and Jung and colleagues, who developed prognostic predictive models for proactively determining patients who should be referred for palliative care \[[@CR29], [@CR30]\]. Our use of a predictive model to improve the performance of a heuristic model increases our capability to determine those in end-of-life care.

The value of using a diagnostic predictive model for determining the probability of subjects in end-of-life care in addition to a heuristic model using administrative codes is for improving the overall sensitivity of finding those subjects in end-of-life care. Our modeling process found subjects who did not have codes in their patient record for end-of-life care but had high probabilities for being in end-of-life care. It is not known why these subjects did not have the codes for end-of-life care. Regardless of the rationale for not including the codes in the patient record, the model provides the capability to reduce systematic bias due to misclassification, in this case classifying those in end-of-life care as not being in end-of-life care. A link to the R package used to create these models is included in Supplementary Appendix 3. This package, along with the instructions, also provided in Supplementary Appendix 3, may be used by researchers in their own studies.

Our models performed well at discriminating end-of-life care from those not in end-of-life care, but were not perfect. We do not recommend removing patients predicted by the model as in end-of-life care. However, our models can be used as a sensitivity analysis for causal inference where we recommend applying the model to any patient with one of the conditions that make them high risk for end-of-life care to assign them a risk of being in end-of-life care. For patients who do not have a condition that makes them high risk, their risk will be 0. This risk value can be used as a covariate in a propensity model or in the outcome model. It would be interesting in future work to see the impact of including our model as a covariate into causal inference studies where end-of-life care is a likely confounder.

There are a number of strengths to the present study. We developed our models using four large datasets covering a wide variety of ages and socioeconomic conditions. In using multiple datasets, we were able to both internally and externally validate each model. Our method used large-scale regularized regression for model development, allowing for the use of factors known to be critical in determining end-of-life care as well as those that may not have been previously known. There were also a number of limitations to our study. The use of administrative datasets primarily maintained for insurance billing is well-known to have significant deficits. Our gold standard for case ascertainment was based on administrative codes for terminal or hospice care, which may be subject to misclassification errors. This model was also developed and validated on people who had at least one of several diagnoses, e.g. cancer, Parkinson's disease, and dementia, therefore it may perform differently on people who do not have any of those diagnoses or whose end of life is not influenced by a chronic disease but by a more acute disease or event (e.g, trauma).

Conclusion {#Sec11}
==========

The models developed for determining those subjects in end-of-life care are an important step forward for improving the validity of exposure risks involving mortality endpoints. Possible next steps would include applying the model to epidemiological studies. Accounting for subjects who received an exposure to a drug or procedure at the point in their treatment when they were in end-of-life care will greatly improve the validity of the risk profile for those treatments.
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